Xtant Medical Holdings Inc (XTNT)
XASE:XTNT
Want to see XTNT full AI Analyst Report?
XTNT Stock Chart & Stats
$0.51
-$0.01(-2.65%)
At close: 4:00 PM EST
$0.51
-$0.01(-2.65%)
Day’s Range― - ―
52-Week Range$0.44 - $0.95
Previous CloseN/A
Volume57.26K
Average Volume (3M)147.07K
Market Cap
$65.22M
Enterprise Value$68.08M
Total Cash (Recent Filing)$12.16M
Total Debt (Recent Filing)$15.44M
Price to Earnings (P/E)35.6
Beta1.00
Next Earnings
Jul 30, 2026EPS Estimate
-0.02Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.04
Shares Outstanding140,262,950
10 Day Avg. Volume170,109
30 Day Avg. Volume147,067
Financial Highlights & Ratios
PEG Ratio-0.16
Price to Book (P/B)2.15
Price to Sales (P/S)0.82
P/FCF Ratio10.76
Enterprise Value/Market Cap1.04
Enterprise Value/Revenue0.56
Enterprise Value/Gross Profit0.90
Enterprise Value/Ebitda6.00
Forecast
1Y Price Target
$1.25Price Target Upside145.10% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
EPS Forecast (FY)0.01
Revenue Forecast (FY)$102.40M
Bulls Say, Bears Say
Bulls Say
Improved Leverage / Balance SheetThe company used proceeds from divestitures to cut total debt by $13.3M and raise revolver availability, materially improving liquidity and lowering interest exposure. This durable capital-structure repair increases financial flexibility for product investment and reduces refinancing risk over the medium term.
Strengthening Cash GenerationXtant produced positive operating and free cash flow in 2025 and the trailing twelve months, signaling an emerging ability to self-fund operations and commercial investments. Sustained cash generation improves resilience to revenue volatility and supports strategic hires and product launches without immediate capital raises.
Portfolio & Commercial ExpansionSecuring exclusive U.S. rights to HEMOBLAST and integrating ~21 experienced reps expands Xtant's addressable market into hemostasis and immediately scales its sales reach. This structural expansion and cross-sell potential diversifies revenue streams beyond legacy lines and supports sustainable top-line growth if commercialization succeeds.
Bears Say
Declining Revenue TrendA sharp year-over-year revenue drop highlights demand loss from divested assets and non‑recurring license streams, and the trailing revenue trajectory was down versus prior periods. Persistent top-line weakness makes sustainable margin recovery and return to growth reliant on successful product rollouts and commercial execution.
Margin And Profitability PressureGross margin compression and very thin trailing net margins leave limited operating cushion for reinvestment or shocks. Even with gross margins expected to recover, the current low net profitability increases sensitivity to sales volatility and planned sales investments, making durable earnings improvement uncertain.
Structural Product Line HeadwindsReimbursement changes and softness in advanced wound care have structurally depressed amnio revenue, while OEM stem-cell sales remain variable. These persistent headwinds create ongoing revenue volatility in key product lines, increasing the burden on new products and distribution deals to deliver steady growth.
Xtant Medical Holdings News
XTNT FAQ
What was Xtant Medical Holdings Inc’s price range in the past 12 months?
Xtant Medical Holdings Inc lowest stock price was $0.44 and its highest was $0.95 in the past 12 months.
What is Xtant Medical Holdings Inc’s market cap?
Xtant Medical Holdings Inc’s market cap is $65.22M.
When is Xtant Medical Holdings Inc’s upcoming earnings report date?
Xtant Medical Holdings Inc’s upcoming earnings report date is Jul 30, 2026 which is in 57 days.
How were Xtant Medical Holdings Inc’s earnings last quarter?
Currently, no data Available
Is Xtant Medical Holdings Inc overvalued?
According to Wall Street analysts Xtant Medical Holdings Inc’s price is currently Undervalued.
Does Xtant Medical Holdings Inc pay dividends?
Xtant Medical Holdings Inc does not currently pay dividends.
What is Xtant Medical Holdings Inc’s EPS estimate?
Xtant Medical Holdings Inc’s EPS estimate is -0.02.
How many shares outstanding does Xtant Medical Holdings Inc have?
Xtant Medical Holdings Inc has 140,262,950 shares outstanding.
What happened to Xtant Medical Holdings Inc’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Xtant Medical Holdings Inc?
Currently, no hedge funds are holding shares in XTNT
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Xtant Medical Holdings Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$1.25 (145.10% Upside)
$1.25 (145.10% Upside)
Blogger Sentiment
Bullish
XTNT Sentiment 70%
Sector Average ―
Sector Average ―
Crowd Wisdom
Very Negative
Last 7 Days ▼ 5.8%
Last 30 Days ▼ 10.2%
Last 30 Days ▼ 10.2%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-29.54%
12-Months-Change
Fundamentals
Return on Equity
3.68%
Trailing 12-Months
Asset Growth
-18.61%
Trailing 12-Months
Company Description
Xtant Medical Holdings Inc
Xtant Medical Holdings, Inc. develops, manufactures, and markets regenerative medicine products and medical devices for orthopedic and neurological surgeons in the United States and internationally. Its biomaterial products include OsteoSponge that provides a natural scaffold for cellular in-growth and exposes bone-forming proteins to the healing environment; OsteoSponge SC that fills bony defects in the subchondral region of joints; OsteoSelect DBM Putty for osteoinductive bone growth; OsteoSelect PLUS DBM Putty for use as a bone void filler and bone graft substitute in the pelvis, extremities, and posterolateral spine; OsteoFactor, which contains various proteins and peptides that support bone formation and remodeling; OsteoWrap; and OsteoVive Plus, a growth factor enriched cellular bone matrix. The company also provides 3Demin, a family of allografts that maximizes osteoconductivity and the osteoinductive potential of human bone. In addition, it processes and distributes sports allografts for anterior and posterior cruciate ligament repairs, anterior cruciate ligament reconstruction, and meniscal repair; milled spinal allografts for cortical bone milled to desired shapes and dimensions; and traditional allografts for orthopedics, neurology, podiatry, oral/maxillofacial, genitourinary, and plastic/reconstructive applications. Further, the company offers Certex spinal fixation, Spider cervical plating, Axle interspinous fusion, Silex Sacroiliac joint fusion, Xpress minimally invasive pedicle screw, and Fortex Pedicle screw systems. Additionally, it provides Calix for cervical and thoracolumbar applications, Axle-X interspinous fusion system, Irix-C cervical integrated fusion system, and Irix-A Lumbar integrated fusion system. The company was formerly known as Bacterin International Holdings, Inc. and changed its name to Xtant Medical Holdings, Inc. in July 2015. Xtant Medical Holdings, Inc. is headquartered in Belgrade, Montana.
XTNT Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Neutral
The call mixed material strategic and balance-sheet positives with near-term operational and revenue challenges. Key strategic wins (HEMOBLAST distribution, Trivium Shaped launch, Companion Spine proceeds) and reduced indebtedness position the company for growth and improved liquidity, and management raised FY2026 revenue guidance. However, Q1 operating metrics were weak: revenue fell ~36.5% year-over-year, gross margin contracted ~4.2 percentage points, the company reported a $3.1M net loss and negative adjusted EBITDA, and cash declined ~29.5% (though revolver availability improved). Management expects margin recovery later in the year and anticipates incremental sales investments to drive adoption, but near-term expense pressure and amnio/OEM headwinds temper the outlook.View all XTNT earnings summariesXTNT Stock 12 Month Forecast
Average Price Target
$1.25
▲(145.10% Upside)
Technical Analysis
Ownership Overview
9.70% Insiders
1.84% Mutual Funds
54.16% Other Institutional Investors
32.86% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---